ClinicalTrials.gg
RecruitingNCT06920134PD-HemONUpdated Jul 7, 2026

Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's Disease

An interventional study of ARC-IM Investigational System in Hypotension Symptomatic, Parkinson's Disease and Orthostatic Hypotension, Dysautonomic, sponsored by Ecole Polytechnique Fédérale de Lausanne. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Ecole Polytechnique Fédérale de Lausanne · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.

Planned enrollment
61st of 67
5 · median 30
Started
2025
with 7 others
No phase
49 of 85
23 open now
Primary completion
2031-05
later than 33 of 33 live
Registered
74th of 85
by date
Lead sponsor
3 of 85
Ecole Polytechnique Fédérale de Lausanne

Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 61st largest by planned enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2025, is one of 49 with no phase, reaches primary completion later than 33 of the 33 other live ones, and was the 74th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Parkinson Disease with a site in Switzerland, or all of them as a file.
02

Study summary

The PD-HemON study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support hemodynamic management in people with typical and atypical Parkinson's Disease, who suffer from orthostatic hypotension.

03

Conditions studied

  • Hypotension Symptomatic
  • Parkinson's Disease
  • Orthostatic Hypotension, Dysautonomic
  • Multiple System Atrophy (MSA) With Orthostatic Hypotension
  • Multiple System Atrophy - Parkinsonian Subtype (MSA-P)

Keywords

  • orthostatic hypotension
  • parkinson's disease
  • autonomic failure
  • hypotension
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. > 18 years old
  2. Typical or Atypical PD (including but not limited to Multiple System Atrophy, Pure Autonomic Failure, Progressive Supranuclear Palsy)
  3. Confirmed orthostatic hypotension with a test for verticalization
  4. Confirmed symptomatic orthostatic hypotension that makes daily activities particularly challenging as determined by the study clinicians
  5. Must provide and sign the before any study-related procedures
  6. Stable medical, physical, and psychological conditions given participant indication as considered by Investigators;
  7. Able to understand and interact with the study team in French or English
  8. Agrees to comply in good faith with all conditions of the study and to attend all scheduled appointments

Exclusion criteria

Exclusion Criteria:

  1. Diseases and conditions that would increase the morbidity and mortality of the implantation surgery
  2. The inability to withhold antiplatelet/anticoagulation agents perioperatively
  3. History of myocardial infarction or cerebrovascular events within the past 6 months
  4. Unstable or significant medical condition that is likely to interfere with study procedures or likely to confound study endpoint evaluations as determined by the Investigator
  5. History or presence of major psychiatric disorders or major neurocognitive disorders as considered by the Investigators in accordance with the treating physician and treating neurologist
  6. Major changes in PD treatment planned until the end of the main study phase (such as DBS or dopamine-pump implantation)
  7. Inability to follow study procedures.
  8. Spinal anatomical abnormalities precluding surgery
  9. Presence of any indications requiring frequent MRIs.
  10. Current pregnancy or current breastfeeding
  11. Lack of effective or acceptable for women of childbearing capacity
  12. Intention to become pregnant during the study
  13. Unable or unwilling to effectively use the study system or related devices by the participant or caretaker, as determined by the investigator
  14. Participation in another interventional study that might confound study endpoint evaluations
  15. Enrolment of the investigator, his/her family members, employees, and other dependent persons
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    All participants

    All participants will be provided with the ARC-IM Investigational System (implantable and non-implan

    Device: ARC-IM Investigational System

Interventions

  • DeviceARC-IM Investigational System

    Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.

06

What researchers measure

Primary outcomes

  1. Occurrence of (serious) adverse device effects of the ARC-IM Therapy from baseline up to the end of the study.

    Evaluate the safety of ARC-IM Therapy in supporting hemodynamic management in participants with atypical or typical Parkinson's Disease and orthostatic hypotension

    Time frame: Throughout the study (up to 5 years)

Secondary outcomes

  1. 10-minute, orthostatic head-up tilt test with and without the ARC-IM Therapy at 1 month after intervention

    Preliminary and long-term efficacy of the ARC-IM Therapy to reduce orthostatic hypotension. Measurement tool: Drop in blood pressure over time (mmHg and sec, mmHg/sec)

    Time frame: At the end of, 6 months after and 1 year after configuration of the therapy,

  2. Severity of symptoms measured by The Orthostatic Hypotension Questionnaire.

    This outcome measures the preliminary long-term efficacy of the ARC-IM Therapy to support hemodynamic instability. The Orthostatic Hypotension Questionnaire (OHQ) has 10 hypotension symptom-related items rated on a 11 point scale (0 - 10). Measurement tool: 0 indicates no symptoms and 10 indicates worst possible severity/outcome. A higher total score indicates worse symptomatology.

    Time frame: At the end of, 6 months after and 1 year after configuration of the therapy

  3. Time Up and Go Test (TUG)

    Preliminary efficacy of the ARC-IM Therapy to improve physical activity. The Time Up and Go will measure time from sit to stand and gait quality. Measurement tool: time (sec)

    Time frame: At the end of, 6 months after and 1 year after configuration of the therapy

  4. 2 Minute Walk Test

    Preliminary efficacy of the ARC-IM Therapy to improve physical activity. The 2 Minute Walk Test (2MWT) will measure gait endurance and distance walked over 2 minutes. Measurement tool: distance (meters)

    Time frame: At the end of, 6 months after and 1 year after configuration of the therapy

  5. Berg Balance Test

    The Berg Balance Test measures the ability to balance safely with 14 specific tasks performed while standing, sitting, or making simple movements. The test scoring ranges from 0 to 56. Measurement tool: lower score indicates greater risk of losing your balance.

    Time frame: At the end of, 6 months after and 1 year after configuration of the therapy

  6. Quebec User Evaluation of Satisfaction with technology (QUEST 2.0)

    To measure the usability of the ARC-IM Main Controller, Clinician Programmer, and Personal Programmer for clinicians and participants. The Quebec User Evaluation of Satisfaction with technology (QUEST 2.0) is a 12-item instrument that evaluates satisfaction with the therapy across form factor, safety, durability, simplicity of use, comfort, service of device and improvements. The evaluation will be performed by a moderator with the participant. Measurement tool: Total score from 12 to 60. Low score means a better outcome.

    Time frame: At 6 months and 1 year after configuration of the therapy

  7. System Usability Scale (SUS)

    Assess the usability of the ARC-IM Main Controller, Clinician Programmer, and Personal Programmer for clinicians and participants. The System Usability Scale (SUS) is a 10-item scale that evaluates the usability and satisfaction of the technology. Measurement tool: Total score from 0 to 100. Higher score indicates better outcome.

    Time frame: At 6 months and 1 year after configuration of the therapy

  8. Additional user feedback of ARC-IM System

    To assess the usability of the ARC-IM Main Controller, Clinician Programmer, and Personal Programmer for clinicians and participants. The Additional user feedback of ARC-IM System is a custom-made user feedback questionnaire to evaluate the overall satisfaction of specific aspects of the therapy including battery life, device communication etc. Measurement tool: Total score where applicable (higher score indicates better outcome) and feedback from participants

    Time frame: At 6 months and 1 year after configuration of the therapy

Other outcomes

  1. Doppler ultrasound to measure cerebral blood perfusion with and without the ARC-IM Therapy

    Time frame: 1 month, 6 months and 12 months post-therapy configuration

  2. Supine hypertension will be evaluated during orthostatic tilt tests without the ARC-IM Therapy

    Measurement tool: blood pressure (mmHg) during supine position of orthostatic tilt test

    Time frame: 1 month, 6 months and 12 months post-therapy configuration

  3. MDS-sponsored Unified Parkinson's Disease Rating Scale Part IB & II

    Participants' quality of life will be assessed with MDS-sponsored Unified Parkinson's Disease Rating Scale Part IB \& II to measure sleep, mental health, and fatigue (MDS-UPDRS-IB \& II) over 20 items. Measurement tool: Total score (0 - 4 rating per question), 0 represents no impairment and 4 represents severe impairment. Higher total score indicates worse symptoms.

    Time frame: 1 month, 6 months and 12 months post-therapy configuration

  4. King's Parkinson's Disease Pain Scale

    Participants' quality of life will be assessed with the 7-item King's Parkinson's Disease Pain Scale to characterize severity and types of pain associated with Parkinson's Disease. Measurement tool: Total score from 0 to 168. Lower score indicates a better outcome.

    Time frame: 1 month, 6 months and 12 months post-therapy configuration

  5. Parkinson's Disease Questionnaire-39 (PDQ-39)

    Participants' quality of life will be measured by the 39 item Parkinson's Disease Questionnaire-39 (PDQ-39) to evaluate perceived health in terms of physical, mental and social functions. Measurement tool: Total score from 0-100, higher scores reflect lower quality of life

    Time frame: 1 month, 6 months and 12 months post-therapy configuration

  6. Scales for Outcomes in Parkinson's disease - Autonomic Dysfunction

    Scales for Outcomes in Parkinson's disease - Autonomic Dysfunction (SCOPA-AUT) is a 25-item, self-completed questionnaire to evaluate autonomic symptoms in people with typical and atypical Parkinson's Disease. Measurement tool: Total score from 0-69 where a higher score indicates increased frequency of autonomic dysfunction symptoms

    Time frame: 1 month, 6 months and 12 months post-therapy configuration

  7. MDS sponsored Unified Parkinson's Disease Rating Scale Part III

    Participants' quality of life will be assessed with the MDS-sponsored Unified Parkinson's Disease Rating Scale Part III (19 items) to evaluate motor function. Measurement tool: Total score from 0 to 132. Low score means a better outcome.

    Time frame: Baseline (before surgery), and 1 month, 6 months and 12 months post-therapy configuration

  8. 24 hour ambulatory measurements

    Participant's quality of life will be evaluated with 24 hour blood pressure measurements with and without the therapy. Measurement tool: blood pressure (mmHg)

    Time frame: Baseline (before surgery), and 1 month, 6 months and 12 months post-therapy configuration

  9. Closed-loop stimulation on management of hemodynamics will be measured with the change in blood pressure during 10 minute, head up tilt tests.

    Closed-loop stimulation will receive feedback from a blood pressure sensor to automatically adjust stimulation intensity. We will evaluate the effects of this stimulation on management of hemodynamics during configuration sessions with pre-configured stimulations, with closed-loop stimulation and without stimulation. The feasibility and effectiveness will be measured by the drop in blood pressure (mmHg) during 10 minute, orthostatic, head-up tilt tests.

    Time frame: Post-operative configuration phases, through year 1 of the study

  10. Time Up and Go Test across different therapeutic conditions

    The complementarity of the ARC-IM Therapy with standard therapies (e.g LDopa) will be assessed over the trajectory of therapy intake with and without stimulation during configuration phases with the Time Up and Go will measure time from sit to stand and gait quality. Measurement tool: time (sec)

    Time frame: Post-operative configuration phases, through year 1 of the study

  11. 2 Minute Walk Test across different therapeutic conditions

    The complementarity of the ARC-IM Therapy with standard therapies (e.g LDopa) will be assessed over the trajectory of therapy intake with and without stimulation during configuration phases with the The 2 Minute Walk Test (2MWT) will measure gait endurance and distance walked over 2 minutes. Measurement tool: distance (meters)

    Time frame: Post-operative configuration phases, through year 1 of the study

  12. Berg Balance Test across different therapeutic conditions

    The complementarity of the ARC-IM Therapy with standard therapies (e.g LDopa) will be assessed over the trajectory of therapy intake with and without stimulation during configuration phases with the Berg Balance Test measures the ability to balance safely with 14 specific tasks performed while standing, sitting, or making simple movements. Measurement tool: Total score from 0-56, lower score indicates greater risk of losing your balance.

    Time frame: Post-operative configuration phases, through year 1 of the study

  13. Montréal Cognitive Assessment (MoCA)

    To objectively characterize and longitudinally monitor cognitive status over the course of the study, the Montréal Cognitive Assessment (MoCA) will be performed. This assessment evaluates several cognitive domains including attention, executive functions, memory, language, visuospatial abilities, abstraction, calculation and orientation. Measurement tool: Total score (0-30), with higher scores indicating better cognitive function.

    Time frame: Baseline, 1 month, 6 months and 12 months post-therapy configuration

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2031, 69 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 69 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Apr 9, 2025
StartActual
Jul 3, 2025
Primary completionEst.
May 1, 2031
CompletionEst.
May 1, 2031
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06920134
Lead sponsor
Ecole Polytechnique Fédérale de Lausanne
Responsible party
Jocelyne Bloch (Professor, Centre Hospitalier Universitaire Vaudois) — Principal investigator
First posted
Apr 9, 2025
Start date
Jul 3, 2025
Primary completion
May 1, 2031 (estimated)
Completion
May 1, 2031 (estimated)
Last update
Jul 7, 2026

Study contacts

Gregoire Courtine, PhD
Contact
gregoire.courtine@epfl.ch
+41 21 69 30762
Jocelyne Bloch, MD
principal investigator · CHUV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion